Department of Pathobiology and Veterinary Science and Center of Excellence for Vaccine Research, College of Agriculture and Natural Resources, University of Connecticut, Storrs, CT 06269, United States.
Department of Pathobiology and Veterinary Science and Center of Excellence for Vaccine Research, College of Agriculture and Natural Resources, University of Connecticut, Storrs, CT 06269, United States.
Virus Res. 2014 Mar 6;181:43-52. doi: 10.1016/j.virusres.2013.12.033. Epub 2014 Jan 3.
The use of vaccinia virus (VACV) as the vaccine against variola virus resulted in the eradication of smallpox. VACV has since been used in the development of recombinant vaccine and therapeutic vectors, but complications associated with uncontrolled viral replication have constrained its use as a live viral vector. We propose to improve the safety of VACV as a live-replicating vector by using elements of the tet operon to control the transcription of genes that are essential for viral growth. Poxviruses encode all enzymes and factors necessary for their replication within the host cell cytoplasm. One essential VACV factor is the vaccinia early transcription factor (VETF) packaged into the viral core. This heterodimeric protein is required for expression of early VACV genes. VETF is composed of a large subunit encoded by the A7L gene and a small subunit encoded by the D6R gene. Two recombinant VACVs were generated in which either the A7L or D6R gene was placed under the control of tet operon elements to allow their transcription, and therefore viral replication, to be dependent on tetracycline antibiotics such as doxycycline. In the absence of inducers, no plaques were produced but abortively infected cells could be identified by expression of a reporter gene. In the presence of doxycycline, both recombinant viruses replicated indistinguishably from the wild-type strain. This stringent control of VACV replication can be used for the development of safer, next-generation VACV vaccines and therapeutic vectors. Such replication-inducible VACVs would only replicate when administered with tetracycline antibiotics, and if adverse events were to occur, treatment would be as simple as antibiotic cessation.
牛痘病毒(VACV)被用作天花病毒的疫苗,导致了天花的根除。此后,VACV 被用于开发重组疫苗和治疗性载体,但与失控的病毒复制相关的并发症限制了其作为活病毒载体的使用。我们建议通过使用 tet 操纵子的元件来控制对病毒生长至关重要的基因的转录,从而提高 VACV 作为活复制载体的安全性。痘病毒在宿主细胞质内编码其复制所需的所有酶和因子。VACV 的一个重要因素是包装在病毒核心内的痘苗早期转录因子(VETF)。这种异源二聚体蛋白是早期 VACV 基因表达所必需的。VETF 由 A7L 基因编码的大亚基和 D6R 基因编码的小亚基组成。生成了两种重组 VACV,其中 A7L 或 D6R 基因被置于 tet 操纵子元件的控制下,以允许它们的转录,从而使病毒复制依赖于四环素类抗生素,如强力霉素。在没有诱导物的情况下,不会产生斑块,但可以通过报告基因的表达鉴定出具有缺陷的感染细胞。在强力霉素存在的情况下,两种重组病毒的复制与野生型菌株没有区别。这种对 VACV 复制的严格控制可用于开发更安全的下一代 VACV 疫苗和治疗性载体。这种复制诱导型 VACV 只有在给予四环素类抗生素时才会复制,如果发生不良反应,治疗就像停止使用抗生素一样简单。